Brought to you by 
Amicus, Biogen enter multi-year agreement in Parkinson's
30 Sep 2013
Executive Summary
Just a day after signing its fourth antisense neurology deal with Isis Pharmaceuticals, Biogen Idec Inc. penned a multi-year agreement with rare disease drug company Amicus Therapeutics Inc. for the discovery, development, and commercialization of small molecules for Parkinson's disease (PD).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com